Genscript Biotech Corporation (HKG:1548)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
25.12
+0.58 (2.36%)
Aug 12, 2026, 11:59 AM HKT

Genscript Biotech Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-532.832,962-95.48-226.85-358.71
Depreciation & Amortization
73.375.7171.8861.1845.86
Other Amortization
0.741.962.173.071.92
Loss (Gain) From Sale of Assets
0.871.190.690.770.91
Asset Writedown & Restructuring Costs
-45.5111.6611.48-
Loss (Gain) From Sale of Investments
391.56-0.19-2.433.64-0.53
Loss (Gain) on Equity Investments
320.3839.071.380.03-
Stock-Based Compensation
14.7976.5260.5965.1539.69
Provision & Write-off of Bad Debts
-1.336.564.781.150.93
Other Operating Activities
59.87-3,020264.61-204.38-9.51
Change in Accounts Receivable
-16.4995.46-116.9938.071.57
Change in Inventory
-8.58-10.53-3.93-19.53-15.14
Change in Accounts Payable
6.9515.99-37.0325.588.07
Change in Unearned Revenue
1.98-35.75100.776.763.54
Change in Other Net Operating Assets
14.3120.28-29.74113.59144.6
Operating Cash Flow
325.5275.65-286.91-120.29-136.79
Operating Cash Flow Growth
330.32%----

Investing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-82.13-195.79-252.45-216.11-133.04
Sale of Property, Plant & Equipment
0.370.240.240.090.27
Sale (Purchase) of Intangibles
-1.76-1.24-4.05-2.27-4.35
Investment in Securities
-83.14-806-101.72-219.75-82.44
Other Investing Activities
-5.29-453.570.25-5.257.02
Investing Cash Flow
-171.95-1,456-357.73-443.3-212.55

Financing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
219.09102.6174.3933.0626.04
Long-Term Debt Repaid
-142.34-67.74-34.06-7.39-74.94
Total Debt Repaid
-142.34-67.74-34.06-7.39-74.94
Net Debt Issued (Repaid)
76.7434.8640.3325.67-48.89
Issuance of Common Stock
6.0213.4917.65228.13951.23
Other Financing Activities
-2.5118.171,010165.52-0.19
Financing Cash Flow
-144.8966.521,068419.32902.14

Net Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
1.82-0.22-1.22-12.7-0.89
Net Cash Flow
10.5-1,314422.4-156.97551.91

Free Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
243.39-120.14-539.36-336.41-269.83
Free Cash Flow Growth
-----
Free Cash Flow Margin
25.36%-20.21%-96.23%-53.76%-55.06%
Free Cash Flow Per Share
0.11-0.06-0.26-0.16-0.13
Levered Free Cash Flow
-67.82425.25-305.28-342.98-176.43
Unlevered Free Cash Flow
-57.01430.27-301.7-334.69-174.95

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
11.544.683.192.041.58
Cash Income Tax Paid
29.2416.62.66-0.660.71
Change in Working Capital
-1.8285.44-86.91164.47142.65